Panic prescribing has become omnipresent during the COVID-19 pandemic

Arthur L. Caplan, Ross Upshur


The President of the United States has repeatedly touted hydroxychloroquine as a likely cure for COVID-19 and urged Americans to try it, stating at one of his media briefings, “What do you have to lose? What do you have to lose? Take it” (1). A few others around the world have chimed in to promote one drug or another, this drug in combination with others, or their own favorite untested nostrums. This has led to drug hoarding, the inability of patients who actually need and benefit from certain drugs to access them, and serious side effects and even deaths from self-medication. Unregistered, untried therapeutics Little noted has been the fact that the world has faced this sort of panic prescribing and recommendation to abandon all efforts at organized study before. Six years ago, on August 12, 2014, the Ebola outbreak led the World Health Organization (WHO) to convene a meeting to decide whether to proceed with evaluation of unregistered, untried therapeutics. Press release “In the particular circumstances of this outbreak, and provided certain conditions are met, the panel reached consensus that it is ethical to offer unproven interventions with as yet unknown efficacy and adverse effects, as potential treatment or prevention. Ethical criteria must guide the provision of such interventions. These include transparency about all aspects of care, informed consent, freedom […]

Find the latest version:

https://jci.me/139562/pdf
Panic prescribing has become omnipresent during the COVID-19 pandemic

Arthur L. Caplan1 and Ross Upshur2,3,4

1Division of Medical Ethics, New York University Grossman School of Medicine, New York, New York, USA. 2Department of Family and Community Medicine and 3Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada. 4Lunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, Ontario, Canada.

The President of the United States has repeatedly touted hydroxychloroquine as a likely cure for COVID-19 and urged Americans to try it, stating at one of his media briefings, “What do you have to lose? What do you have to lose? Take it” (1). A few others around the world have chimed in to promote one drug or another, this drug in combination with others, or their own favorite untested nostrums. This has led to drug hoarding, the inability of patients who actually need and benefit from certain drugs to access them, and serious side effects and even deaths from self-medication.

Unregistered, untried therapeutics

Little noted has been the fact that the world has faced this sort of panic prescribing and recommendation to abandon all efforts at organized study before. Six years ago, on August 12, 2014, the Ebola outbreak led the World Health Organization (WHO) to convene a meeting to decide whether to proceed with evaluation of unregistered, untried therapeutics.

Press release

“In the particular circumstances of this outbreak, and provided certain conditions are met, the panel reached consensus that it is ethical to offer unproven interventions with as yet unknown efficacy and adverse effects, as potential treatment or prevention.

Ethical criteria must guide the provision of such interventions. These include transparency about all aspects of care, informed consent, freedom of choice, confidentiality, respect for the person, preservation of dignity, and involvement of the community.

In order to understand the safety and efficacy of these interventions, the group advised that, if and when they are used to treat patients, there is a moral obligation to collect and share all data generated, including from treatments provided for ‘compassionate use’ (access to an unapproved drug outside of a clinical trial)” (2).

As it was unclear at the time whether any benefit would come from these interventions, a mechanism called monitored emergency use of unregistered and investigational interventions (MEURI) was created as a bridge to clinical trials in order to curtail unconstrained use of medications.

By August 12, 2019, the Data and Safety Monitoring Board recommended early termination of a Democratic Republic of the Congo (DRC) randomized control trial; by October 18, 2019, a safe vaccine had been identified.

Accelerated implementation and evaluation of interventions

After 5 years, the world went from a situation where Ebola infection was regarded as a dreaded, nearly universally fatal disease that could neither be treated nor prevented to a disease with a registered vaccine and two monoclonal antibodies with significantly positive treatment effects (3, 4). What is worth noting is the accelerated implementation and evaluation of these interventions — the global coordination and funding to go from a situation of therapeutic nihilism, panic, and despair to one of optimism and hope.

The most remarkable aspect of this narrative is that the research was carried out in some of the most rudimentary and under-resourced health systems in the world. Clinical trials were initiated in West Africa from 2014 to 2016. However, despite mathematical models predicting large numbers of cases, the outbreak was ebbing when the clinical trials started in December 2014. Even then, it was possible to get trials designed and approved in less than four months. The final clinical trial in the DRC took place under exceptionally difficult circumstances, including civil conflict and political instability. Moreover, the research was conducted according to good clinical practice standards, was approved by local and international ethics committees, and met agreed-upon standards for the protection of human subjects. In this case, the science and ethics worked well together, and a noteworthy result occurred (5).

It would be foolish to argue that the path for studying treatments for Ebola was entirely smooth. There were principled disagreements on the nature of study designs, the inclusion of placebo controls, the nature of community engagement, and the adequacy of informed consent, particularly for the collection, storage, and transport of data and tissues. However, the debates led to consensus (6, 7).

These lessons are clearly applicable to the SARS-CoV-2 pandemic. It is possible to develop an effective clinical research response that can generate answers to priority questions in a rapid fashion. This is the intention behind the Solidarity trial, a multinational adaptive randomized platform design (8). The virtue of this design is the capacity to discard ineffective treatments and add promising options for evaluation in the same core protocol. Efforts should be devoted to participating in well-founded trials and avoiding small, underpowered trials, as they are noninformative and squander resources.

Clinical trials in infectious disease emergencies can be conducted without derogating human subjects’ protection and watering down research ethics stan-
The way forward is not medicine by anecdote, panic prescribing, hoarding, or testimonials. The way to find safe and effective interventions is to use adaptive platforms of adequate power alongside compassionate use of novel agents in a manner that permits the accumulation of knowledge. Hope drives research to find answers — it’s not a substitute for solutions.

Acknowledgments

ALC wishes to acknowledge the feedback of members of the NYU School of Medicine Working Group on Compassionate Use and Preapproval Access.

Address correspondence to: Arthur L. Caplan, 227 East 30th Street 7th Floor Room 722, New York, New York 10016, USA. Email: arthur.caplan@nyulangone.org.


The Journal of Clinical Investigation